Crispr Therapeutics shares tumble after significant earnings miss
Ronald Owen Whitford Jr., Senior Vice President, General Counsel, and Secretary at BWX Technologies, Inc. (NYSE:BWXT), executed a series of stock transactions recently. On February 27, Whitford sold 2,000 shares of common stock at a price of $104.925 per share, totaling approximately $209,850. The transaction occurred near the stock’s current trading level of $103.97, with the company commanding a market capitalization of $9.3 billion and trading at a P/E ratio of 34x.
In addition to the sale, Whitford also reported a transaction involving the withholding of 232 shares for tax purposes, valued at $106.64 per share, amounting to $24,740. The transactions were part of a broader set of activities, including the acquisition of 540 shares of common stock through the exercise of restricted stock units. According to InvestingPro analysis, BWXT has maintained strong financial health, with liquid assets exceeding short-term obligations.
Whitford’s transactions reflect routine financial management activities, including stock sales and exercises, as part of his compensation package. Following these transactions, Whitford holds 9,904 shares of BWX Technologies’ common stock. Analysts maintain a positive outlook on BWXT, with price targets ranging from $105 to $166 per share. For deeper insights into BWXT’s valuation and financial metrics, including 14 additional ProTips and comprehensive analysis, check out the detailed research report available on InvestingPro.
In other recent news, BWX Technologies Inc. (BWXT) reported its fourth-quarter 2024 earnings, significantly surpassing market expectations. The company achieved an earnings per share (EPS) of $0.92, exceeding the forecasted $0.81, and reported revenue of $746.3 million, which was above the anticipated $722.25 million. For the full year, BWXT set records in revenue, adjusted EBITDA, adjusted EPS, and free cash flow, driven by strong demand in national security, clean energy, and medical markets. Looking ahead, BWXT has provided optimistic guidance for 2025, projecting revenue of approximately $3 billion and adjusted EBITDA between $550 million and $570 million. The company’s strategic acquisitions, including the recent completion of AOT and plans to acquire Conetrics Incorporated, are expected to bolster its capabilities in nuclear technologies and medical isotopes. Analysts from Deutsche Bank (ETR:DBKGn) and other firms have shown interest in BWXT’s progress, particularly in its microreactor development and potential tariff impacts. The company remains focused on strategic investments and expansions in its nuclear and medical sectors to maintain its competitive edge.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.